Seres Therapeutics (MCRB) Operating Expenses (2014 - 2026)

Seres Therapeutics has disclosed Operating Expenses across 13 years of filings, most recently posting $22.0 million for Q2 2026.

• In Q2 2026, Operating Expenses fell 11.54% year-over-year to $22.0 million; the TTM figure through Jun 2026 stood at $85.9 million (down 21.98% YoY), while the FY2025 annual figure was $94.8 million, down 21.89% from the prior year.
• Operating Expenses came in at $22.0 million for Q2 2026 at Seres Therapeutics, up from $21.3 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $76.9 million in Q2 2023 to a low of -$4.4 million in Q4 2022.
• Average Operating Expenses over 5 years is $37.1 million, with a median of $29.0 million recorded in 2024.
• Year-over-year, Operating Expenses plunged 107.81% in 2022 and soared 937.27% in 2023.
• Over 5 years, Operating Expenses stood at -$4.4 million in 2022, then soared by 937.27% to $37.0 million in 2023, then slipped by 22.12% to $28.8 million in 2024, then plunged by 31.28% to $19.8 million in 2025, then gained by 11.07% to $22.0 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $22.0 million in Q2 2026, $21.3 million in Q1 2026, and $19.8 million in Q4 2025.